Nautilus Biotechnology could become extraordinarily important to oncology by reading intact proteoform states across cancer's redundant signaling pathways. Before-and-after tumor measurements could train AI to find the smallest effective, tumor-specific drug combination beyond mutation-guided care. It has not shown it can map every clinically relevant cancer proteoform or prescribe curative combinations. AI-biology companies must buy Nautilus now or face painfully compressed margins. x.com  x.com 

Peptide R&D could be a major tailwind for Nautilus Biotechnology because developers need proteoform data to understand treatment effects. Demand could rise next year if peptide success drives R&D, depending on its rollout and assays. AI-driven biology also needs measurements to validate models regardless of which therapies win. Personalized peptide care is years or a decade away, requiring clinical validation, approval and much cheaper profiling; Nautilus must still prove scale and economics. … Show more

Nautilus Biotechnology is wildly overvalued at about $250M on just $190K of trailing-12-month revenue, a price richer than early-stage VC. That rebuts @alc2022's case that it owns the read layer for the proteome and could return 100-1,000x. x.com 

Voyager's single-molecule approach could make Nautilus the most asymmetric proteomics bet if it works. Quarterly grant revenue of about $0.2m against over $10m consumed leaves it reliant on capital; a $125m ATM risks dilution. Repeated slips make the mid-2027 launch less likely to hold; independent customer validation and a sales channel are absent. Adoption could justify billions; delay or low-price issuance could send shares below $2 again. Tempus AI remains the preferred larger holding. x.com 

Zeta Global and Nautilus Biotechnology are two versions of the same idea, seeing deeper than anyone else: Zeta into the customer, Nautilus into the molecule. Both are aligned with something everyone wants, better information, and moved first to build the platforms that deliver it. Neither guarantees success, but both greatly raise the odds, which creates the asymmetry. Zeta is much further along in its zero-to-one journey. x.com 

Nautilus Biotechnology remains too speculative and faces eventual Nasdaq delisting if it cannot hold above $1. A price floor just under $1 after its collapse looks technically supportive, and there are early signs of commercial interest, but it is still a wild card. x.com 

The AI and biology basket now adds AbCellera and Hims & Hers and looks set to destroy the market over the next 10 years. ImmunityBio is the immune system's operating system, Nautilus is the Tesla of proteomics, Recursion is superhuman biology-chemistry AI, AbCellera is the machine that can hit any target in the body, and Hims & Hers is the dominant direct-to-consumer distribution layer. x.com 

Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

Hims & Hers, Nautilus Biotechnology, Viking Therapeutics, Protagonist Therapeutics and Eli Lilly have 10x potential as peptide-related stocks; peptides will create generational wealth this year. Nautilus has a $230 million market cap, Viking $3.5 billion, Protagonist $9.1 billion and Lilly $1.1 trillion. x.com  x.com  x.com  x.com  x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more